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BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population.
The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently
diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural
history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on
the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End
Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared
between black men and the general population. RESULTS: The models projected that from 30% to 43% (range across models) of
black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general
population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared
with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to
75% higher than that in the general population. CONCLUSIONS: Prostate cancer incidence patterns implicate higher incidence of pre-
clinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than
white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer
2017;123:2312-9. VC 2017 American Cancer Society.
KEYWORDS: cancer epidemiology, mass screening, natural history, prostate-specific antigen, prostatic neoplasms, racial disparities,
statistical methods and models.
INTRODUCTION
Prostate cancer is the most frequent cancer diagnosis and the second leading cause of cancer death in US men. Prostate
cancer incidence among black men in the United States is 60% higher and mortality is more than double the rate observed
in white men.1
There is an extensive literature exploring likely drivers of the racial disparity in prostate cancer observed in the United
States. Regarding mortality, a persistent question concerns the relative contributions of differential access to care versus
biology. Some studies2,3 have suggested that differential access to care may partially explain the greater burden of adverse
outcomes among black men. Others have identified differences in germline and tumor genetics between black men and
white men.1,4-6 Black race has been identified as an independent prognostic factor for disease recurrence in multiple
reports,7,8 supporting a biologically more aggressive disease phenotype but also raising questions about disparities in sur-
gery quality.9 In general, black men are less likely to receive primary surgery,10-12 but the extent to which this observation
is related to demographics, access to care, or personal preference is unclear.
At least 1 major driver behind the higher rate of prostate cancer deaths among black men is their higher incidence of
the disease. Taksler et al concluded that the majority (76%) of the disparity in prostate cancer mortality may be explained
by higher prostate cancer incidence in black men.13 The objective of the current study was to investigate and explain the
higher observed incidence in black men. Whether this arises from a higher risk of disease onset or faster progression to an
aggressive or symptomatic state is unclear. In their multiethnic study of UK men, Metcalfe et al14 suggested that the latter
is unlikely; however, they did not formally interrogate this hypothesis.
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Understanding whether and how natural history
might be different in black men is important because, if
black men have a higher susceptibility to prostate cancer
and/or a greater tendency to develop aggressive disease,
then it may be of value to consider different screening pol-
icies for them. This issue was first raised by Powell et al,15
who observed more aggressive disease characteristics and
more frequent recurrence among black men after radical
prostatectomy and, again,16 based on a narrowing of pros-
tate cancer survival disparities observed after the adoption
of prostate-specific antigen (PSA) screening in the United
States.
We previously studied the natural history of prostate
cancer in the general population through statistical and
computer modeling of latent disease onset and progres-
sion to clinical and metastatic states.17-19 By calibrating
the models to observed population patterns of prostate
cancer incidence before and after the advent of PSA
screening, we estimated the risks of critical events in dis-
ease natural history and used these results to make infer-
ences about potential impacts of different screening
policies.20,21
In this article, we develop versions of our natural his-
tory models that pertain to black men and calibrate these
using incidence trends in the Surveillance, Epidemiology,
and End Results (SEER) program under updated PSA
screening frequencies estimated specifically among the
black population. We use the calibrated models to pro-
duce estimates of disease onset, progression, and diagnosis
risks that pertain to the black population. We compare
these risks with estimates for the general population (ie,
all races) to determine the extent to which the increased
incidence among black men is explained by higher risks of
disease onset, progression, or diagnosis. Finally, we use
our results to examine differential incidence of clinically
relevant disease, motivating further research into differen-
tial screening policies among black men.
MATERIALS AND METHODS
In this section, we describe the data and 3 models that we
use to examine evidence of differential prostate cancer nat-
ural history in black men. We also describe a test for dif-
ferences in black natural history relative to the general
population and quantify the models’ goodness-of-fit after
re-estimating key components of natural history.
PSA Screening and Prostate Cancer Incidence
Data
Because the use of population-based PSA screening was
not tracked in real time, we retrospectively reconstructed
PSA screening patterns in the United States separately for
black men and white men in a previous study.22 Briefly,
this reconstruction used responses to the National Health
Interview Survey (NHIS) in 2000 to estimate the age at
first PSA test and longitudinal claims data from the linked
SEER-Medicare database to estimate the distribution of
interscreening intervals. The current version of the PSA
screening model updates the original version, incorporat-
ing responses to the 2005 NHIS as well as information on
changes in disease-specific incidence after the advent of
PSA (for a comparison of the original and updated PSA
screening models, see the online supporting information).
We extracted prostate cancer incidence data from
the SEER database before and after the introduction of
PSA screening. Specifically, we extracted prostate cancer
incidence for men ages 50 to 84 years from 1975 through
2000, SEER historic locoregional and distant states,
tumor grade (well or moderately differentiated [low
grade] vs poorly differentiated or undifferentiated [high
grade]), and race categories (“black” or “all races”). Miss-
ing information on stage, grade, and race was assumed to
be missing at random and was imputed as the most fre-
quent combination of 20 logistic regression imputations
using themice package in R.23
Three Models of Prostate Cancer Natural
History
We estimated 3 models of prostate cancer natural history
using PSA screening and prostate cancer incidence data
separately for black men and for all races. The 3 models
were previously used to study the effects of PSA screening
on incidence and mortality trends in the general US
population.24,25
Briefly, the Fred Hutchinson Cancer Research Cen-
ter (FHCRC) model is a microsimulation model that
links individual PSA growth and cancer progression. In
this model, higher and increasing PSA levels are associated
with the presence of latent cancer, and shorter intervals
are associated with metastatic spread and clinical presenta-
tion. The Microsimulation Screening Analysis (MIS-
CAN) model (from Memorial Sloan-Kettering Cancer
Center) is a microsimulation model that tracks progres-
sion through combinations of cancer stages and grades. In
this model, advanced stages and higher grades are associat-
ed with potentially higher screening test sensitivity and
shorter intervals to clinical presentation. The UMICH
model (from the University of Michigan Comprehensive
Cancer Center) is an integrated suite of analytic models
that estimates transition probabilities from earlier to later
stages and from lower to higher grades during the
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preclinical detectable phase. In this model, later stage at
onset, higher grade at onset, and faster progression are
associated independently with shorter intervals to clinical
presentation. In each model, screening potentially detects
latent cancer at an earlier stage and/or grade. Key differ-
ences between models are the length of the preclinical
detectable phase, how much early detection improves
tumor characteristics, and how both natural history and
screening effects depend on age. Detailed descriptions of
the models are provided in the online supporting
information.
A Framework to Explain Incidence Disparities
Sequential estimation
We first re-estimated natural history in all races using the
SEER incidence and updated PSA screening data. Then,
we substituted PSA screening patterns for black men and
re-estimated natural history in black men after a systemat-
ic sequence of steps. Specifically, we re-estimated compo-
nents of disease natural history, each containing a specific
block of parameters. The blocks of parameters governed:
1) risk of disease onset and initial tumor features, 2) risks
of progression to metastasis and/or high-grade disease,
and 3) risk of clinical diagnosis. At each step, the re-
estimation involved identifying values of the natural histo-
ry parameters that allowed the models to most closely
match SEER prostate cancer incidence in black men. All
models proceeded in this sequential fashion until final ver-
sions of the models were obtained that re-estimated all
natural history parameters for black men. To evaluate sen-
sitivity to this sequence of re-estimated parameters, a
model-selection exercise was used to examine alternative
sequences.
Natural history summary measures
Given the final versions of the models for black men and
for all races, we summarized natural history in terms of
the risks of preclinical onset, clinical diagnosis, and meta-
static clinical diagnosis; mean ages at these natural history
events; and mean years between consecutive events.
Because all models were calibrated using data up to age 85
years, the summary measures were truncated at this age.
Testing and quantifying contributions to incidence
disparities
We used a likelihood ratio test to evaluate whether re-
estimating components of disease natural history signifi-
cantly improved the models’ fits to the incidence data for
black men. The likelihood used age at diagnosis as a sur-
vival time and was fit using a customized age-period
approach.19 To calculate likelihood ratio statistics, 2
likelihood functions were fit, 1 with and 1 without re-
estimation of the component. Although we report the
likelihood ratio test results, we anticipate that, given the
large sample size in the SEER registry, all tests will be
highly significant at a traditional threshold. Therefore, we
also report the improvement in the goodness-of-fit
achieved by re-estimating components of natural history,
with goodness-of-fit expressed as the sum across years of
the squared difference between annual model-projected
and observed age-adjusted incidence rates.
RESULTS
Figure 1 illustrates the annual percentage of men ages 50
to 84 years who received at least 1 PSA test by race and age
group over the period from 1988 through 2000 using
responses from the 2005 NHIS. Relative to previous esti-
mates using responses from the 2000 NHIS,22 we observe
that younger men received fewer tests; these differences
were similar among black men and men of all races. The
updated screening patterns indicate that, relative to the
general population, modestly lower percentages of black
men received at least 1 PSA test in all but the youngest
ages throughout the 1990s. The greatest racial disparities
in PSA testing were in the oldest ages.
Figure 2 illustrates the results from re-estimating
natural history for all races. The figure shows age-adjusted
prostate cancer incidence rates per 100,000 men ages 50
to 84 years reported in SEER by historic stage and corre-
sponding model-projected incidence rates. Figure 2 also
provides SEER incidence rates for black men and results
from the sequential estimation of the models’ natural his-
tory components. The sequential estimation indicates
that allowing the risk of disease onset to be different for
black men provided an immediate improvement in the
models’ fits to incidence in this population. Allowing the
risk of progression to distant stage to be different pro-
duced higher distant stage incidence projections but simi-
lar locoregional stage incidence projections. Also,
allowing the risk of clinical diagnosis to differ in black
men provided modest improvements to the fit in some
cases (eg, distant stage incidence in the FHCRC model).
Results of the model-selection exercise described in the
online supporting information demonstrate that this
sequence for re-estimating parameter blocks reflects
descending importance in the improvements in fits.
Improvements from re-estimating each block of nat-
ural history parameters were highly statistically significant
from likelihood ratio tests (all P < .0001), and the final
models’ fits to stage-specific incidence were substantially
improved by re-estimation of the natural history
Original Article
2314 Cancer June 15, 2017
components. The online supporting information indi-
cates that sums of squared differences between observed
and projected, age-adjusted incidence rates declined dra-
matically once disease onset was re-estimated, confirming
the relative importance of disease onset risk in explaining
incidence disparities. All models obtained the best fits
(ie, the smallest errors) when all parameter blocks were
re-estimated.
Table 1 summarizes natural history measures among
black men and for men of all races up to age 85 years esti-
mated by the 3 final models. In the general population,
the risk of developing preclinical disease is 24% to 29%
(range across models). In black men, however, these risks
rise to 30% to 43%, reflecting risks that are (relatively)
28% to 56% higher than those in the general population.
According to the models, the risks of clinical diagnosis in
black men are (relatively) 33% to 70% higher than the
general population; the corresponding observed risk in
SEER before the advent of PSA screening was 53% higher
in black men than in white men (range, 42%-62% higher)
over the period from 1975 to 1986. Among men who
have had disease onset, the risk of clinical diagnosis is
comparable for blacks (35%-49% across models) and all
races (32%-44% across models), and this translates into
sojourn times from disease onset to diagnosis that are very
similar for black men and for the general population with-
in each model. However, among men with preclinical dis-
ease, the models estimate a 44% to 75% higher risk of
metastasis before diagnosis among black men, reflecting
greater risk of progression in this population.
DISCUSSION
The observation that prostate cancer diagnosis is more
common and more lethal among black men than among
white men has never been fully explained. Our study uses
3 models,17-19 which previously were calibrated to US
population incidence trends, to learn about features of
underlying disease onset and progression that are unaf-
fected by differential practice patterns around prostate
cancer screening and diagnosis. The model results consis-
tently demonstrated that the risk of onset of a preclinical
prostate cancer explains a large majority of the observed
incidence disparities. Furthermore, in addition to the risk
of onset, the risk of progression to metastatic disease
before clinical diagnosis was higher among black men, but
their risk of clinical diagnosis after disease onset was simi-
lar to that in the general population. The models cannot
identify whether these apparent differences in disease nat-
ural history are driven by biology, behavioral, or environ-
mental factors, but they are of value in generating
hypotheses about underlying mechanisms and their impli-
cations for screening policies.
On the basis of these results, we conclude that black
men have more preclinical and progressive prostate cancer
than men in the general population. They are more likely
to develop prostate cancer at a younger age, and they are
more likely to progress to a metastatic state and/or higher
grade before clinical diagnosis. Their higher risk of pro-
gression agrees with a previous study based on autopsy
and surgical pathology data26, which concluded that black
men had an earlier transformation to clinically significant
cancer than white men. That study indicated similar age-
specific prevalence of prostate cancer among autopsies
conducted in black and white men from the Detroit met-
ropolitan area between 1992 and 2001. The study also
reported evidence of more aggressive disease in radical
prostatectomy specimens from black men, consistent with
their markedly higher incidence of metastatic disease at
diagnosis. These findings led the authors to conclude that
the risk of prostate cancer initiation did not differ by race,
but the risk of disease progression was higher among black
men. However, similar latent prevalence and greater met-
astatic clinical incidence of disease among black men in
Figure 1. The annual percentage of men who receive at least 1
prostate-specific antigen (PSA) test is illustrated based on
the updated reconstruction of PSA screening patterns in the
United States.
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fact is only possible if latent incidence is also higher in this
subgroup. Because, if latent incidence is similar among
black men but progression is faster, then this actually
would lead to lower latent prevalence at autopsy. There-
fore, we conclude that the prior study results are indeed
consistent with our finding that the risks of both latent
incidence and progression are likely higher among black
men.
Our findings motivate considering more intensive
screening, eg, beginning earlier and/or screening more fre-
quently, among black men than among the general US
population. To illustrate this, Figure 3 illustrates the
cumulative incidence of “relevant disease,” ie, disease
fated to present before other-cause death. At all ages, the
cumulative incidence is higher for black men than for
men of all races. At ages 46 to 52 years (range across mod-
els), the cumulative incidence among black men reaches
the value estimated at age 55 years among all races. Thus,
if it is agreed that prostate cancer screening is worthwhile,
and if starting at age 55 years is determined for the general
population, then our results suggest starting from 3 to 9
years earlier for black men.
We recognize that a consensus about general popula-
tion screening is still lacking. The US Preventive Services
Task Force27 recommends against routine prostate cancer
screening in men of average risk, whereas the American
Figure 2. Age-adjusted prostate cancer incidence rates per 100,000 men ages 50 to 84 years are illustrated for black men (black
line) and for all races (gray line) along with corresponding projections by 3 models (colored lines). Model projections are based
on the models estimated for all races combined with prostate-specific antigen screening among black men and sequentially re-
estimating components of natural history to allow differential risk of onset of preclinical cancer (“onset”), risk of progression to
metastasis and/or higher grade disease (“progression”), and risk of clinical diagnosis (“diagnosis”). FHCRC indicates the Fred
Hutchinson Cancer Research Center model; MISCAN, Microsimulation Screening Analysis (Erasmus University Medical Center
model); N/A, not applicable; SEER, the National Cancer Institute Surveillance, Epidemiology, and End Results program; UMICH,
the University of Michigan model.
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Cancer Society28 recommends shared decision making
around prostate cancer screening beginning at age 50
years, and the American Urological Association29 pro-
vides similar guidance with a starting age of 55 years.
However, black men are not at average risk, and the
benefit-harm tradeoffs of screening are likely to be differ-
ent for this population.30
Although starting screening at an earlier age is
unlikely to impact overdiagnosis, other more aggressive
screening policies, eg, shortening intervals between
screens or lowering the PSA threshold for biopsy referral,
could increase risks of overdiagnosis.31 A comprehensive
policy-development process addressing whether and how
best to screen black men will have to carefully weigh
benefit-harm tradeoffs of candidate policies. Understand-
ing race-specific natural history will be a critical prerequi-
site for this important work. At this point, however, our
findings support considering screening beginning at an
earlier age in black men than in the general
population. Powell et al16 also recommend aggressive,
TABLE 1. Summary Measures for Natural History Events Occurring Within a Man’s Lifetime, up to Age 85
Years, Projected by the 3 Models
FHCRC MISCAN UMICH
Measure
Black
Men
All
Races Ratioa
Black
Men
All
Races Ratioa
Black
Men
All
Races Ratioa
Risk of onset, % 43 28 1.56 30 24 1.28 37 29 1.29
Risk of clinical diagnosis, % 15 9 1.70 13 10 1.33 18 13 1.44
Risk of metastatic clinical diagnosis, % 4 2 2.53 4 2 1.84 4 2 2.26
Risk of clinical diagnosis given onset, % 35 32 1.09 45 43 1.04 49 44 1.12
Risk of metastatic clinical diagnosis given onset, % 9 6 1.63 13 9 1.44 12 7 1.75
Mean age at onset, y 57 59 0.97 64 67 0.96 65 66 0.99
Mean age at clinical diagnosis, y 71 72 0.99 70 72 0.98 75 76 0.98
Mean age at metastatic clinical diagnosis, y 70 72 0.98 71 73 0.98 74 74 0.99
Mean time from onset to clinical diagnosis, y 18 18 1.02 10 10 0.98 17 18 0.92
Mean time from onset to metastatic clinical diagnosis, y 16 15 1.03 12 13 0.94 16 21 0.79
Risk of PSA or clinical diagnosis, %b 16 10 1.65 20 16 1.23 20 14 1.45
Risk of PSA or clinical diagnosis given onset, %b 38 36 1.06 66 68 0.97 53 47 1.12
Mean age at PSA or clinical diagnosis, yb 70 71 0.99 69 71 0.98 73 74 0.98
Mean time from PSA to clinical diagnosis, yb 7 7 1.03 8 9 0.95 7 7 0.96
Abbreviations: FHCRC, Fred Hutchinson Cancer Research Center model; MISCAN, Microsimulation Screening Analysis (Erasmus University Medical Center
model); PSA, prostate-specific antigen; UMICH, the University of Michigan model.
a Ratios are for black men relative to all races and are calculated using 4 significant digits for all measures.
b These measures are in the presence of modeled PSA screening patterns during 1987 through 2000 and are included for reference.
Figure 3. The cumulative incidence of the onset of preclinical prostate cancer that would be clinically diagnosed in black men
and in men of all races projected by the models is illustrated. Line segments indicate the ages at which black men have incidence
corresponding to levels estimated at age 55 years in all races. FHCRC indicates Fred Hutchinson Cancer Research Center model;
MISCAN, Microsimulation Screening Analysis (Erasmus University Medical Center model); UMICH, the University of Michigan
model.
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early prostate cancer PSA testing of African American
men. Our work adds to theirs by illustrating 1 quantita-
tive justification for an age at which to initiate screening
in black men.
In practice, the policy-development process will
require going beyond examining incidence patterns to
projecting mortality in the presence and absence of screen-
ing. Because screening benefit is contingent on access to
efficacious therapies, benefits of screening in different race
groups may be affected by any disparities in access to treat-
ment and any racial differences in treatment efficacy.
Future work will extend the models used in this article to
project the downstream outcomes of different screening
policies in black men under race-specific treatment distri-
butions and efficacies.
Limitations of this study relate primarily to model-
ing assumptions and data limitations. Although the use
of multiple models provides some sense of robustness to
the specific assumptions made, all models assume that
disease is progressive. Thus, none of the models explicitly
include an indolent subpopulation, although each allows
heterogeneity of disease progression, with some cases
progressing rapidly and others slowly. The FHCRC
model allows the likelihood of developing high-grade
disease to vary with age but does not model grade pro-
gression; the other models allow both grade and stage
progression. Other differences across models are also
driven by differences in the conceptualization of onset
and how the risk of onset depends on age. In the FHCRC
model, onset refers to the latent incidence of disease that
would be detectable by biopsy, which can occur as early
as age 35 years; whereas, in the MISCAN and UMICH
models, onset refers to the latent incidence of disease that
can be detected based on elevated PSA and diagnostic
workup, and this rarely occurs before age 40 years. Final-
ly, the PSA screening rates used by all models are based
on a retrospective reconstruction rather than a prospec-
tive tracking of prostate cancer screening dissemination
in the US population.
In conclusion, this study represents the first exami-
nation of how prostate cancer natural history must differ
in black men to account for racial variation in patterns of
disease incidence before and after the advent of PSA
screening. We use observed patterns of disease incidence
and screening to learn about key events in the latent pro-
cess of disease by race. Our results provide quantitative
information about the prostate cancer natural history that
may support prior suggestions to explore different screen-
ing policies among white men and black men.13,15
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